摘要
慢性阻塞性肺病(COPD)是目前世界范围内发病率和病死率持续上升的常见慢性气道疾病。依据最新的2015年版GOLD指南,对于稳定期COPD的治疗目标是缓解症状和降低远期急性加重风险;支气管舒张剂可通过改变气道平滑肌张力,舒张支气管,改善气流受限,缓解呼吸困难,提高患者生活质量,是治疗稳定期COPD的一线基础药物。而β_2受体激动剂是临床上最常用的支气管舒张剂,简介β_2受体激动剂的作用机制,主要对短效、长效和不同给药途径的β_2受体激动剂用于治疗COPD的临床研究进展作一综述。
Chronic obstructive pulmonary disease（COPD） is a common chronic airway disease with growing morbidity and mortality worldwide. According to the Global Initiative for Chronic Obstructive Lung Disease（GOLD） Updated 2015, the goal of pharmacologic therapy for stable COPD is to relieve symptoms and reduce the frequency and severity of exacerbations. As the first-line therapy for stable COPD, bronchodilators could dilate bronchus, improve airflow limitation and relieve dyspnea by altering airway smooth muscle tone, thus improving the life quality of COPD patients. β_2-adrenoceptor agonists are the most commonly used bronchodilators in clinical setting. The acting mechanism of β_2-adrenoceptor agonists was introduced. The clinical research progress of short-acting and long-acting β_2-adrenoceptor agonists with different rontes of administration for the treatment of COPD was mainly reviewed.
出处
《药学进展》
CAS
2016年第5期363-369,共7页
Progress in Pharmaceutical Sciences
基金
国家自然科学基金(No.81273571)
关键词
Β2受体激动剂
慢性阻塞性肺病
支气管舒张剂
临床研究
β2-adrenoceptor agonist
chronic obstructive pulmonary disease
bronchodilator
clinical research
